Trials / Completed
CompletedNCT06673667
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study Designed to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-621 in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Kymera Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KT-621 | Oral drug |
| DRUG | Placebo | Oral drug |
Timeline
- Start date
- 2024-10-22
- Primary completion
- 2025-04-23
- Completion
- 2025-04-23
- First posted
- 2024-11-05
- Last updated
- 2025-10-02
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06673667. Inclusion in this directory is not an endorsement.